7,500 Shares in Globus Medical, Inc. (NYSE:GMED) Acquired by Blue Capital Inc.

Blue Capital Inc. bought a new stake in Globus Medical, Inc. (NYSE:GMED - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 7,500 shares of the medical device company's stock, valued at approximately $620,000.

A number of other institutional investors have also modified their holdings of GMED. SBI Securities Co. Ltd. acquired a new stake in shares of Globus Medical in the fourth quarter valued at $27,000. UMB Bank n.a. raised its stake in Globus Medical by 60.2% during the 4th quarter. UMB Bank n.a. now owns 548 shares of the medical device company's stock valued at $45,000 after acquiring an additional 206 shares during the last quarter. V Square Quantitative Management LLC increased its stake in Globus Medical by 52.0% in the 4th quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company's stock valued at $48,000 after buying an additional 197 shares during the period. First Horizon Advisors Inc. increased its stake in shares of Globus Medical by 24.7% during the fourth quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company's stock worth $55,000 after acquiring an additional 132 shares during the period. Finally, Huntington National Bank raised its stake in shares of Globus Medical by 47.8% during the 4th quarter. Huntington National Bank now owns 958 shares of the medical device company's stock worth $79,000 after buying an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Canaccord Genuity Group raised their price target on shares of Globus Medical from $92.00 to $101.00 and gave the stock a "buy" rating in a research note on Friday, January 10th. Barclays boosted their price objective on Globus Medical from $100.00 to $103.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Bank of America raised Globus Medical from an "underperform" rating to a "neutral" rating and increased their price target for the company from $80.00 to $97.00 in a report on Thursday, January 9th. Wells Fargo & Company lowered their price objective on Globus Medical from $95.00 to $93.00 and set an "overweight" rating for the company in a report on Friday, February 21st. Finally, Stifel Nicolaus increased their price target on Globus Medical from $92.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Globus Medical presently has a consensus rating of "Moderate Buy" and an average target price of $96.91.

Globus Medical Trading Up 1.7 %

NYSE GMED traded up $1.16 during trading on Wednesday, reaching $71.59. The company's stock had a trading volume of 1,127,488 shares, compared to its average volume of 1,042,744. The firm has a market capitalization of $9.85 billion, a price-to-earnings ratio of 95.46, a price-to-earnings-growth ratio of 1.61 and a beta of 1.32. The firm has a 50 day moving average price of $72.80 and a 200 day moving average price of $79.98. Globus Medical, Inc. has a 12 month low of $58.20 and a 12 month high of $94.93.

Globus Medical (NYSE:GMED - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million for the quarter, compared to analyst estimates of $646.19 million. On average, equities analysts forecast that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.